Currently holds positions in CRISPR Therapeutics AG, Genocea Biosciences Inc and Adaptimmune Therapeutics PLC
Position | Company | Period |
---|---|---|
Independent Director | CRISPR Therapeutics AG | April 1, 2015 - |
Independent Director | Genocea Biosciences Inc | Feb. 8, 2018 - |
Non-Executive Independent Director | Adaptimmune Therapeutics PLC | Sept. 1, 2014 - |
Independent Director | Nevro Corp | Sept. 1, 2014 - March 19, 2019 |
Search
Notification date | Transaction date | B/S Transaction type |
Nb. shares Price Value |
Number of shares | Price | Total value | Details | |
---|---|---|---|---|---|---|---|---|
2023-07-19 | 2023-07-17 |
Savara Inc
(SVRA)
|
B Purchase |
333,333
+1.4%
3.00999,999 USD |
333,333 +1.4% | 3.00 | 999,999 USD | |
2022-05-26 | 2022-05-25 |
Genocea Biosciences Inc
(GNCA)
|
S Sale |
4,445,093
-100.0%
0.08362,720 USD |
4,445,093 -100.0% | 0.08 | 362,720 USD | |
2022-05-26 | 2022-05-24 |
Genocea Biosciences Inc
(GNCA)
|
S Sale |
5,931,843
-57.2%
0.07387,943 USD |
5,931,843 -57.2% | 0.07 | 387,943 USD | |
2022-04-13 | 2022-04-11 |
Trevi Therapeutics Inc
(TRVI)
|
B Purchase |
948,948
+inf%
1.901,803,001 USD |
948,948 +inf% | 1.90 | 1,803,001 USD | |
2022-04-13 | 2022-04-11 |
Trevi Therapeutics Inc
(TRVI)
|
B Purchase |
2,631,578
+33.8%
1.904,999,998 USD |
2,631,578 +33.8% | 1.90 | 4,999,998 USD | |
2021-10-19 | 2021-10-18 |
Trevi Therapeutics Inc
(TRVI)
|
B Purchase |
1,851,852
0.000 USD |
1,851,852 | 0.00 | 0 USD | |
2021-03-18 | 2021-03-16 |
Marker Therapeutics Inc
(MRKR)
|
B Purchase |
5,714,285
+114.3%
1.759,999,999 USD |
5,714,285 +114.3% | 1.75 | 9,999,999 USD | |
2020-12-07 | 2020-12-04 |
Regulus Therapeutics Inc
(RGLS)
|
B Purchase |
4,398,602
+214.3%
0.622,735,930 USD |
4,398,602 +214.3% | 0.62 | 2,735,930 USD | |
2020-09-22 | 2020-09-18 |
Metacrine, Inc.
(MTCR)
|
B Purchase |
769,230
+33.6%
13.009,999,990 USD |
769,230 +33.6% | 13.00 | 9,999,990 USD | |
2020-07-28 | 2020-07-24 |
Genocea Biosciences Inc
(GNCA)
|
B Purchase |
3,151,260
+43.6%
2.257,090,335 USD |
3,151,260 +43.6% | 2.25 | 7,090,335 USD | |
2020-07-01 | 2020-06-30 |
Akouos Inc
(AKUS)
|
B Purchase |
588,235
+15.9%
17.009,999,995 USD |
588,235 +15.9% | 17.00 | 9,999,995 USD | |
2020-04-13 | 2020-04-03 |
Trevi Therapeutics Inc
(TRVI)
|
S Sale |
564
-0.0%
2.661,500 USD |
564 -0.0% | 2.66 | 1,500 USD | |
2020-02-05 | 2020-02-03 | B Purchase |
800,000
+30.2%
19.0015,200,000 USD |
800,000 +30.2% | 19.00 | 15,200,000 USD | ||
2020-01-28 | 2020-01-24 |
Adaptimmune Therapeutics PLC
(ADAP)
|
B Purchase |
7,500,000
+62.5%
0.675,000,250 USD |
7,500,000 +62.5% | 0.67 | 5,000,250 USD | |
2019-07-24 | 2019-07-22 |
Mirum Pharmaceuticals Inc
(MIRM)
|
B Purchase |
450,000
+12.0%
15.006,750,000 USD |
450,000 +12.0% | 15.00 | 6,750,000 USD | |
2019-06-25 | 2019-06-24 |
Genocea Biosciences Inc
(GNCA)
|
B Purchase |
2,857,142
+65.4%
3.509,999,997 USD |
2,857,142 +65.4% | 3.50 | 9,999,997 USD | |
2019-05-13 | 2019-05-09 |
Trevi Therapeutics Inc
(TRVI)
|
B Purchase |
1,500,000
+51.0%
10.0015,000,000 USD |
1,500,000 +51.0% | 10.00 | 15,000,000 USD | |
2019-05-13 | 2019-05-09 |
Trevi Therapeutics Inc
(TRVI)
|
B Purchase |
1,000,000
+51.6%
10.0010,000,000 USD |
1,000,000 +51.6% | 10.00 | 10,000,000 USD | |
2019-05-09 | 2019-05-07 |
Regulus Therapeutics Inc
(RGLS)
|
B Purchase |
1,136,704
+124.1%
1.081,227,640 USD |
1,136,704 +124.1% | 1.08 | 1,227,640 USD | |
2019-02-19 | 2019-02-14 |
Genocea Biosciences Inc
(GNCA)
|
B Purchase |
9,948,269
+39.8%
0.474,688,619 USD |
9,948,269 +39.8% | 0.47 | 4,688,619 USD |